Kodiak Sciences Inc.
KOD
Rank in Stocks
#3153
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Share Price
$90.83
Last synced: 2026-10-19
Market Cap
$5.71B
Change (1 day)
5.92%
Change (1 year)
413.16%
Country
US
Trade Kodiak Sciences Inc. (KOD)
Category
Healthcare
Number of shares outstanding for Kodiak Sciences Inc. (KOD)
Number of shares outstanding as of June 2026: 62.63M
According to Kodiak Sciences Inc. latest financial reports and stock price the company's current number of shares outstanding is 62.63M. At the end of December 2023 the company had 52.41M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Kodiak Sciences Inc. (KOD) from 2016 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 62.63M | 19.10% |
| 2024 | 52.58M | 0.32% |
| 2023 | 52.41M | 0.31% |
| 2022 | 52.25M | 0.89% |
| 2021 | 51.79M | 13.22% |
| 2020 | 45.74M | 20.84% |
| 2019 | 37.85M | 5.53% |
| 2018 | 35.87M | 35.08% |
| 2017 | 26.56M | 256.75% |
| 2016 | 7.44M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 305.41% |
US
|
|
| 396.00M | 532.30% |
US
|
|
| 478.91M | 664.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -0.71% |
NL
|
